Showing 6681-6690 of 20911 results for "".
- Evaluating Non-Surgical Alternatives in the Treatment of Nodular Basal Cell Carcinomahttps://reachmd.com/news/evaluating-non-surgical-alternatives-in-the-treatment-of-nodular-basal-cell-carcinoma/2473862/A recent five-year randomized clinical trial comparing non-surgical and surgical treatments for nodular basal cell carcinoma underscores that while non-invasive methods may offer superior cosmetic outcomes, they are less effective in ensuring long-term success compared with
- Advancements in Dermatology: The Role of Telemedicine and Topical Treatmentshttps://reachmd.com/news/advancements-in-dermatology-the-role-of-telemedicine-and-topical-treatments/2471392/The integration of telemedicine in dermatology has significantly improved patient satisfaction and access to care, while topical treatments offer a targeted approach for chronic itch, especially in older patients. These advancements are reshaping clinical practices and pati
- Global Underuse of Cardiovascular Medications Calls for Actionhttps://reachmd.com/news/global-underuse-of-cardiovascular-medications-calls-for-action/2471390/A recent international study highlights significant underuse of vital medications for cardiovascular disease prevention worldwide, pointing to a need for enhanced healthcare strategies. Significance This information is crucial as it identifies a large gap in
- Uncovering Lung Cancer’s Metabolic Weakness: The Role of GUK1 Enzymehttps://reachmd.com/news/uncovering-lung-cancers-metabolic-weakness-the-role-of-guk1-enzyme/2471386/Recent research has identified a crucial enzyme, GUK1, that could revolutionize lung cancer treatment by targeting cancer cell metabolism, providing potential new avenues for therapy. The Enzyme GUK1: A New Frontier in Cancer Treatment
- Sanofi to Present Data on Dupilumab for BP, AD, CSU, PN, Plus Amlitelimabhttps://reachmd.com/news/Sanofi-Present-Data-Dupilumab-BP-AD-CSU-PN-Plus-Amlitelimab/2471384/Sanofi will present 26 abstracts, including one late-breaking and five additional oral presentations, across approved and investigational medicines at the American Academy of Dermatology (AAD) Annual Meeting in Orlando, Florida, from March 7-11. Presentations in partnership with Regeneron
- Novartis to Present CSU, HS Data for Remibrutinib, Secukinumabhttps://reachmd.com/news/Novartis-Present-CSU-HS-Data-Remibrutinib-Secukinumab/2471383/Novartis announced it will present data from 17 abstracts, including investigator-initiated trials, across its immunology portfolio at the 2025 American Academy of Dermatology (AAD) Annual Meeting and the 2025 American Academy of Allergy Asthma and Immunology (AAAAI) and World Allergy Organizatio
- Analysis: Nicotinamide Not Linked to Elevated MACE Riskhttps://reachmd.com/news/study-nicotinamide-not-linked-to-mace-risk/2471380/Results from a new retrospective cohort study suggest nicotinamide exposure was not associated with an increased risk of major adverse cardiovascular events (MACE). The analysis included data from 13,108 patients in the Vanderb
- Link Between Rheumatoid Arthritis and Prostate Cancer Riskhttps://reachmd.com/news/link-between-rheumatoid-arthritis-and-prostate-cancer-risk/2471347/What's New Emerging research highlights a potential link between rheumatoid arthritis and increased prostate cancer risk, urging healthcare providers to consider new screening guidelines for patients with autoimmune conditions. Significance This find
- Examining Long-Term Effects of Post-COVID-19 Syndromehttps://reachmd.com/news/examining-long-term-effects-of-post-covid-19-syndrome/2471350/What's New A recent study highlights that two-thirds of individuals with post-COVID-19 syndrome experience persistent symptoms, emphasizing the need for continued patient evaluation and care. Significance This research underscores the necessity for o
- The Role of AI in Enhancing Cancer Treatment Effectivenesshttps://reachmd.com/news/the-role-of-ai-in-enhancing-cancer-treatment-effectiveness/2471358/What's New A groundbreaking study reveals how artificial intelligence (AI) can improve cancer treatment strategies by collaborating with oncologists to make personalized patient care more effective. Significance This advancement is significant as it